In a market obsessed with public metrics and viral growth, Intabio represents the ultimate counter-narrative: a stealth biotech with $35M in funding, 27 employees, and absolutely zero digital footprint. This isn't a failure—it's a calculated strategy.

"Silence isn't absence—it's a moat. While competitors market vaporware, Intabio is building."

The leadership team signals enterprise-level ambition. Maggie Ostrowski (Director, Strategic Marketing) and Walter Ausserer (Vice-President, Corporate Development & Marketing) aren't junior hires—they're seasoned operators who understand that in biotech, credibility trumps visibility. Their presence suggests a company preparing for partnerships, not direct-to-consumer plays.

• Zero digital footprint = proprietary advantage in biotech IP race
• 27 employees = focused R&D team, not bloated org
• $35M funding = validation from sophisticated biotech VCs
• Strategic marketing leadership = preparing for partnership announcements